Autosomal dominant spastic paraplegia type 12 is a rare genetic condition that mainly causes progressive stiffness and weakness in the legs. People with this condition often notice walking changes, leg cramps, or frequent tripping, and doctors may see increased muscle tone and brisk reflexes. Symptoms usually begin in childhood to mid-adulthood and tend to slowly worsen over many years. ADSPG12 is lifelong but not typically life-shortening, though severity can vary. Treatment focuses on managing symptoms with physical therapy, stretching, mobility aids, and medicines to reduce spasticity, and talking with your healthcare provider can bring clarity and reassurance.
Overview
Autosomal dominant spastic paraplegia type 12Symptoms
Early symptoms of autosomal dominant spastic paraplegia type 12 include leg stiffness, muscle tightness, and tripping or a gait change. Over time, walking difficulty, leg weakness, and cramps can worsen. Some also have bladder urgency, foot numbness, or balance problems.
Outlook and prognosis
Many people with autosomal dominant spastic paraplegia type 12 (SPG12) notice slowly worsening leg stiffness and balance issues over years, sometimes decades. Life span is usually unaffected, and thoughtful rehab, mobility aids, and symptom‑targeted medicines can maintain independence. Outlook varies by family and age of onset.
Causes and risk factors
Autosomal dominant spastic paraplegia type 12 results from a single gene change inherited in an autosomal dominant way. Risk is highest with an affected biological parent; sometimes a new mutation occurs. No proven environmental or lifestyle causes.
Genetic influences
Genetics is central in autosomal dominant spastic paraplegia type 12. A single altered copy of a causative gene can trigger the condition, and each child has a 50% chance of inheriting it. Variants influence age at onset, severity, and progression.
Diagnosis
Doctors suspect autosomal dominant spastic paraplegia type 12 based on typical walking stiffness, leg spasticity, and family history, after excluding other causes with exam and MRI. A multigene panel confirms the genetic diagnosis of autosomal dominant spastic paraplegia type 12.
Treatment and drugs
Treatment for autosomal dominant spastic paraplegia type 12 focuses on easing stiffness, improving mobility, and supporting daily function. Many benefit from regular physiotherapy, stretching, and targeted strength work, plus medications like baclofen or tizanidine for spasticity. Occupational therapy, mobility aids, and fall-prevention strategies help maintain independence.
Symptoms
Walking can start to feel stiff or effortful, with legs that tighten and resist quick movements. Features vary from person to person and can change over time. Autosomal dominant spastic paraplegia type 12 mainly affects the lower body, leading to tight leg muscles (spasticity), overactive reflexes, and changes in the way you walk. Early features of Autosomal dominant spastic paraplegia type 12 often show up as leg stiffness, tripping on uneven ground, or urinary urgency, while thinking and arm strength are usually unaffected.
Tight, hard-to-relax muscles in the thighs and calves can make movement feel rigid. This muscle tightness (spasticity) may stand out after sitting or when you try to walk faster.
Steps may get shorter and legs can feel like they pull inward or cross slightly. This gait pattern is typical in Autosomal dominant spastic paraplegia type 12.
The hips and ankles can feel less powerful, making stairs or rising from a chair harder. You may notice the legs tire sooner during longer walks.
Tripping, toe catching, or occasional falls can happen, especially on uneven ground. Turning quickly or walking in crowded spaces may feel unsteady.
How people usually first notice Autosomal dominant spastic paraplegia type 12?
Many families first notice something is different when a child or teenager develops a stiff, scissoring gait or frequent tripping that slowly worsens, even though strength seems mostly intact. Doctors often pick up brisk reflexes, ankle clonus, and tightness in the hamstrings and calves during an exam, and a family history of similar walking difficulties across generations can raise suspicion for the first signs of autosomal dominant spastic paraplegia type 12. Some people are not recognized until adulthood, when gradually increasing leg stiffness, fatigue with walking, or new balance problems prompt evaluation and genetic testing to clarify how autosomal dominant spastic paraplegia type 12 is first noticed.
Types of Autosomal dominant spastic paraplegia type 12
Autosomal dominant spastic paraplegia type 12 (SPG12) is a genetic, inherited condition, and experts describe clinical variants rather than symptom categories. These variants reflect how the same gene change can lead to different patterns of movement symptoms and other features across families. People may notice different sets of symptoms depending on their situation. When reading about types of SPG12, you’ll often see “pure” and “complex” forms described, which are the main, widely accepted variants of this condition.
Pure SPG12
This form mainly causes stiffness and weakness in the legs with gradual walking difficulty. Reflexes are brisk, and vibration sense near the ankles may be reduced, but other body systems are usually spared.
Complex SPG12
This form includes leg stiffness and weakness plus additional features such as mild nerve involvement in the feet or subtle coordination, speech, or cognitive changes. Severity can vary from mild extras to more noticeable day‑to‑day impact in some families.
What genetics can tell you about symptoms
Some people with autosomal dominant spastic paraplegia type 12 (SPG12), caused by pathogenic variants in the RTN2 gene, develop slowly progressive leg stiffness, muscle spasms, and walking difficulties from corticospinal tract damage. Certain variants can also bring sensory changes, mild neuropathy, or bladder symptoms.
Causes and risk factors
Autosomal dominant spastic paraplegia type 12 is caused by a change in a gene called RTN2.
It is inherited in an autosomal dominant pattern, so a parent with the gene change has a 50% chance to pass it to each child.
Some risks are written in our DNA, passed down through families.
Many cases run in families, and a family history of autosomal dominant spastic paraplegia type 12 is the main risk for relatives, but a new gene change can also appear for the first time.
Lifestyle and environment do not cause this condition, but other genes, general health, and activity level may influence when symptoms start and how severe they become.
Environmental and biological risk factors
When planning a pregnancy, it’s natural to wonder what might raise the chance that a rare condition could occur. For autosomal dominant spastic paraplegia type 12, the key considerations are factors that affect whether a new change arises in egg or sperm before conception. Doctors often group risks into internal (biological) and external (environmental). Below are environmental and biological risk factors for autosomal dominant spastic paraplegia type 12 that relate to how often it arises in a child.
New changes in sperm become more frequent as fathers get older, which can raise the chance that a child is born with autosomal dominant spastic paraplegia type 12. The absolute risk for any one pregnancy remains low.
As maternal age increases, eggs are more likely to carry new changes that were not present earlier in life. This may modestly increase the chance that a condition arises due to a new change. Most pregnancies at older ages do not involve this outcome.
Exposure of the ovaries or testes to high-dose ionizing radiation can damage DNA in reproductive cells. By increasing the chance of new changes, this could slightly increase the likelihood of autosomal dominant spastic paraplegia type 12 in a child. Everyday diagnostic imaging uses far lower doses than those associated with this effect.
Some chemotherapy medicines and pelvic radiation can harm eggs or sperm and increase DNA damage. If exposure happens before conception, the chance of new changes in reproductive cells can rise. Any added risk is expected to be small and depends on the specific treatment and dose.
Genetic risk factors
Genetic risk for Autosomal dominant spastic paraplegia type 12 centers on inherited changes in a single gene and on family history. Some risk factors are inherited through our genes. A parent with a confirmed disease-causing change can pass it to children, but how and when symptoms appear can differ even within the same family. Genetic testing can clarify who carries the change.
RTN2 gene: Harmful changes in the RTN2 gene are the known genetic cause of Autosomal dominant spastic paraplegia type 12. RTN2 helps the long wiring of nerve cells work properly, and a faulty copy can disturb that system.
Autosomal dominant pattern: Autosomal dominant spastic paraplegia type 12 can result from a single altered RTN2 copy. Each child of an affected parent has a 50% (1 in 2) chance of inheriting the same change.
De novo changes: A new RTN2 change can appear in someone with no family history. When this happens, brothers and sisters usually have a low chance of being affected, but the person’s children each face a 50% risk.
Family history: Having a parent or sibling with a confirmed RTN2 variant greatly increases personal risk. If a specific family change is known, targeted genetic testing can show who carries it.
Age-related onset: Some people who carry the RTN2 change develop signs later in adulthood, while others notice issues earlier. This can make early symptoms of Autosomal dominant spastic paraplegia type 12 less obvious in families until multiple adults are affected.
Severity differences: The same RTN2 change can lead to very mild or more noticeable movement changes in different relatives. This variation means course and timing can differ widely between families.
Genetic modifiers: Other genes can nudge when symptoms start and how they progress, even with the same RTN2 change. Science continues to uncover how these elements interact.
Parental mosaicism: Rarely, a parent without symptoms can carry the change in a portion of their egg or sperm cells. This can slightly raise the chance of another child being affected, even when blood testing in the parent is negative.
Lifestyle risk factors
Autosomal dominant spastic paraplegia type 12 is a genetic condition; lifestyle habits do not cause it, but they can shape symptom burden, mobility, and complications. Understanding how lifestyle affects Autosomal dominant spastic paraplegia type 12 can guide choices that support gait and daily function. In practical terms, the lifestyle risk factors for Autosomal dominant spastic paraplegia type 12 are behaviors that increase spasticity, deconditioning, fatigue, falls, or bowel/bladder issues.
Targeted stretching and strengthening can reduce spasticity and improve gait efficiency in SPG12. Consistent practice may slow secondary deconditioning and delay joint contractures.
Prolonged sitting increases stiffness and worsens spasticity in SPG12. Breaking up sitting with brief movement bouts can ease walking and reduce fall risk.
Low‑impact cardio maintains endurance and may lessen fatigue in SPG12. Overexertion can transiently heighten spasticity, so gradual progression and cooldowns help.
Daily hamstring, calf, and hip stretches can improve stride length and reduce clonus in SPG12. Regular range‑of‑motion work may delay contractures at hips, knees, and ankles.
Risk prevention
Autosomal dominant spastic paraplegia type 12 is an inherited condition, so you can’t prevent the gene change itself. Prevention focuses on lowering the chances of complications like falls, contractures, urinary issues, pressure sores, and bone loss. Early, steady care can help you stay mobile and independent, especially if you act when early symptoms of autosomal dominant spastic paraplegia type 12 start to show. Different people need different prevention strategies—there’s no single formula.
A genetics professional can explain inheritance, chances for children, and testing options. Some families consider preimplantation genetic testing or prenatal testing when planning a pregnancy.
Ongoing care helps fine-tune spasticity treatments and address pain or stiffness before they lead to falls. Regular reviews also catch new symptoms early so care can be adjusted.
Daily stretching keeps muscles flexible and helps prevent contractures that limit movement. A therapist can tailor a home program and update it as needs change.
Low-impact activities like cycling, swimming, or water therapy can support strength and endurance without overstraining. Gradual, supervised training helps protect joints and balance.
Transmission
Autosomal dominant spastic paraplegia type 12 is a genetic condition and isn’t contagious—you can’t catch it from someone else. It follows an autosomal dominant pattern: someone with the condition has one altered gene copy, and each child has a 50% chance of inheriting it. Many families have multiple affected generations, but sometimes the genetic change happens for the first time in a child, so there may be no earlier family history. How Autosomal dominant spastic paraplegia type 12 is inherited doesn’t change from person to person, though symptoms can be milder or more pronounced even within the same family. If you’re planning a family, a genetics professional can explain the genetic transmission of Autosomal dominant spastic paraplegia type 12 and discuss testing options.
When to test your genes
Consider genetic testing if you have unexplained progressive leg stiffness/weakness, a family history of spastic paraplegia or related gait problems, or symptoms beginning in youth to mid-adulthood. Testing can confirm SPG12, guide surveillance (falls, bladder issues), inform treatment choices, and clarify risks for relatives. Discuss timing with a genetics clinician.
Diagnosis
Autosomal dominant spastic paraplegia type 12 is usually picked up when walking becomes stiff or unsteady and leg muscles feel tight, especially after standing or walking for a while. Doctors look for a pattern of slowly progressive leg stiffness and overactive reflexes, then use tests to confirm and rule out other causes. Getting a diagnosis is often a turning point toward answers and support. The diagnosis of Autosomal dominant spastic paraplegia type 12 is confirmed with genetic testing after the clinical picture fits.
Doctors assess leg stiffness, reflexes, balance, and walking pattern. A consistent pattern of tight leg muscles with brisk reflexes supports the diagnosis. Subtle changes in vibration sense or foot position awareness may also be checked.
A detailed family and health history can help identify similar symptoms across generations. This condition often runs in families in an autosomal dominant pattern. Knowing who else is affected can focus testing.
Brain and spinal MRI help rule out stroke, multiple sclerosis, spinal cord compression, or other structural causes. Imaging may look normal in many people with this condition. Once the scan is complete, your doctor may recommend further tests.
Testing looks for a disease‑causing change in the RTN2 gene, or uses a hereditary spastic paraplegia panel. A positive result provides confirmation and can guide family counseling. Genetic diagnosis of Autosomal dominant spastic paraplegia type 12 is the most specific way to confirm the condition.
Stages of Autosomal dominant spastic paraplegia type 12
Autosomal dominant spastic paraplegia type 12 does not have defined progression stages. Symptoms often build slowly and vary from person to person, so there isn’t a standard early–mid–late pattern. Doctors typically diagnose it by reviewing walking changes and leg stiffness, doing a neurological exam, and using imaging if needed; early symptoms of autosomal dominant spastic paraplegia type 12 can include subtle balance changes or a feeling of tightness in the legs that leads to a check-up. Genetic testing may be offered to clarify certain risks.
Outlook and prognosis
Looking ahead can feel daunting, but many people with autosomal dominant spastic paraplegia type 12 (SPG12) build stable routines that keep them moving, working, and engaged. Symptoms usually center on slowly progressive leg stiffness and weakness; for some, fine hand movements or mild balance and bladder issues join in over time. The outlook is not the same for everyone, but many living with SPG12 notice a very gradual change across years rather than months, with long plateaus where function feels steady.
Doctors call this the prognosis—a medical word for likely outcomes. Most people with SPG12 have a normal life expectancy, and life‑threatening complications are uncommon when mobility, falls, and bladder health are proactively managed. Some people experience only walking stiffness that starts in adulthood, while others notice earlier onset with added features like tremor or subtle thinking changes. Early care can make a real difference—consistent physical therapy, spasticity management, fall‑proofing the home, and attention to mood and fatigue often preserve independence and confidence.
Understanding the prognosis can guide planning and help you track early symptoms of autosomal dominant spastic paraplegia type 12, such as new tripping, toe dragging, or rising effort on stairs. In medical terms, the long-term outlook is often shaped by both genetics and lifestyle, so two relatives with the same gene change may progress differently. Talk with your doctor about what your personal outlook might look like, including how often to reassess walking speed, muscle tone, and bladder function, and when to consider medications, braces, or mobility aids. With ongoing care, many people maintain meaningful activity, safe mobility, and strong social connections for decades.
Long-term effects
Over time, many living with autosomal dominant spastic paraplegia type 12 notice walking becomes slower and less steady, especially on uneven ground or stairs. Long-term effects vary widely, with some changes staying mild for years while others progress more noticeably. For many, the condition moves slowly, and life expectancy is usually near typical. Thinking about the long-term effects helps set expectations for mobility, comfort, and daily independence.
Tight, resistant muscles in the legs can gradually limit stride length and speed. Early symptoms of autosomal dominant spastic paraplegia type 12 may include subtle leg stiffness that slowly builds.
Leg weakness may develop alongside stiffness, making hills and rising from chairs harder. This can slowly narrow the safe walking distance indoors and outdoors.
Unsteady footing can lead to tripping or falls, especially when turning or on uneven surfaces. Some may need more support in dim light or when tired.
Urgent or frequent urination can emerge and persist over the years. Nighttime bathroom trips may increase and interrupt sleep.
How is it to live with Autosomal dominant spastic paraplegia type 12?
Living with autosomal dominant spastic paraplegia type 12 often means planning your day around stiffness and gradually increasing leg weakness, with walking becoming slower, less steady, and more effortful over time. Many find that fatigue builds faster, stairs and long distances are tougher, and falls or near-falls make them more cautious; canes, walkers, or braces may become practical tools rather than signs of decline. Family and friends often step in with rides, help carrying items, or pacing outings, and because this condition can run in families, conversations about genetic testing, future planning, and support for younger relatives may surface. With regular physical therapy, smart home adjustments, and an honest pace that respects energy limits, many keep working, parenting, and staying socially active—just with more intention and a bit of backup.
Treatment and drugs
Autosomal dominant spastic paraplegia type 12 (SPG12) is managed by easing symptoms, protecting mobility, and supporting daily function; there’s no single cure yet. Treatment often looks different for each person, but most plans include regular physiotherapy to stretch tight leg muscles, strengthen core and hip support, and improve balance, plus occupational therapy to adapt home and work tasks. Medicines that ease symptoms are called antispasmodics, and doctors may use options like baclofen, tizanidine, or botulinum toxin for troublesome muscle stiffness, along with pain relievers if cramps or neuropathic pain occur; a doctor may adjust your dose to balance benefits and side effects. For walking, many with spastic paraplegia benefit from ankle–foot orthoses, canes, or walkers, and some use intrathecal baclofen pumps if oral drugs don’t help enough. Alongside medical treatment, lifestyle choices play a role, including regular low-impact exercise (like swimming or cycling), fall-prevention strategies, timely management of bladder or bowel symptoms, and periodic check-ins with a neurologist and rehabilitation team to update the plan as needs change.
Non-drug treatment
Living with autosomal dominant spastic paraplegia type 12 often means planning for stiffness, balance changes, and fatigue in everyday routines. Non-drug treatments often lay the foundation for staying mobile, steady, and independent. A team approach—rehab therapists, mobility specialists, and genetic counselors—can tailor care to your goals. As needs change over time, plans are adjusted to keep life moving safely and comfortably.
Tailored stretching, strengthening, and posture work keep legs looser and walking steadier. Starting therapy during early symptoms of autosomal dominant spastic paraplegia type 12 can slow day-to-day decline. Regular tune-ups help prevent setbacks.
Practice with safe turning, speed changes, and stairs lowers fall risk. Therapists use cueing and treadmill or over-ground drills to improve stride. Home exercises maintain gains.
Daily calf, hamstring, and hip stretches ease stiffness and cramps. Night splints or gentle positioning can reduce morning tightness. Heat or self-massage may make stretching easier.
Canes, trekking poles, walkers, or rollators improve stability and confidence. An ankle-foot brace can reduce toe drag and trips. Reassessing devices as autosomal dominant spastic paraplegia type 12 progresses keeps walking safer.
Your genes may have an impact on how drugs work for you
Genes can change how your body processes medicines for autosomal dominant spastic paraplegia type 12, affecting dose needs and side‑effects. Pharmacogenetic testing and family history can guide safer choices for muscle relaxants, pain control, and mood or sleep medications.
Pharmacological treatments
Drug treatment for autosomal dominant spastic paraplegia type 12 (SPG12) focuses on easing stiffness, spasms, pain, and bladder or bowel symptoms. There isn’t a cure yet, so medicines are chosen based on the symptoms that affect day-to-day movement and comfort. People often ask about medications for spasticity in autosomal dominant spastic paraplegia type 12, and several options can help. Not everyone responds to the same medication in the same way.
This muscle relaxer can ease leg stiffness and spasms and is often a first choice. Dosing may be increased or lowered gradually to find the right balance of benefit and side effects.
Helpful for spasticity and cramping, especially later in the day. It can make some people sleepy or lightheaded, so bedtime dosing is common.
Works directly on muscle to reduce tightness and spasms. Liver monitoring may be needed with longer-term use.
Diazepam or clonazepam can calm nighttime spasms and help sleep. They can cause drowsiness and are usually used short-term or as add-ons.
Genetic influences
Genetic changes play a central role here, most often affecting a gene that helps long nerve fibers stay healthy in the spinal cord. Autosomal dominant spastic paraplegia type 12 usually follows an autosomal dominant pattern: if a parent carries the change, each child has a 50% chance of inheriting it. In some families there’s no previous history because the gene change arises for the first time in the person diagnosed. Having a gene change doesn’t always mean you will develop the condition. Severity and the age when symptoms begin can differ widely, even among relatives with the same change. Genetic testing for autosomal dominant spastic paraplegia type 12 can look for changes in the RTN2 gene and may help confirm the cause, guide family planning, and identify relatives who could be at risk.
Is Autosomal dominant spastic paraplegia type 12 genetic?
Genetics is central in autosomal dominant spastic paraplegia type 12. A single altered copy of a causative gene can trigger the condition, and each child has a 50% chance of inheriting it. Variants influence age at onset, severity, and progression.
Pharmacogenetics—how genetics influence drug effects
Treatment for Autosomal dominant spastic paraplegia type 12 focuses on easing stiffness, spasms, and related symptoms, and genetics can influence how you respond to some of these medicines. The gene change that causes the condition doesn’t yet point to a specific drug, but other genes that guide how your liver breaks down medicines can affect common options like muscle relaxers (for example, tizanidine), benzodiazepines such as diazepam, certain antidepressants, and some pain relievers. Genetic testing can sometimes identify how your body processes certain medicines, which may help doctors choose a dose that’s safer and more effective. For example, differences in certain liver enzymes can change how strongly you feel a medicine’s effect or side effects, while baclofen is cleared mostly by the kidneys. This is why two people may need very different doses, or even different drugs, to get the same relief. Other factors—age, kidney and liver health, and interactions with other prescriptions—also play a role, so any changes should be guided by a clinician familiar with medication response in Autosomal dominant spastic paraplegia type 12.
Interactions with other conditions
For people with Autosomal dominant spastic paraplegia type 12, living with other health issues can change how symptoms feel day to day. Diabetes-related nerve damage (peripheral neuropathy), for example, can compound leg weakness and numbness, making walking and balance more difficult. Urinary tract infections or other illnesses with fever often ramp up muscle tightness and spasms; a condition may “exacerbate” (make worse) symptoms of another. Joint problems like hip or knee osteoarthritis, or spinal stenosis, can add pain and stiffness, so it’s harder to tell what is coming from Autosomal dominant spastic paraplegia type 12 versus a coexisting orthopedic issue. Mood disorders such as anxiety or depression are not rare in long-term neurologic conditions and can drain energy, lower activity levels, and indirectly worsen mobility and sleep. Because some neurological diseases share pathways that affect long nerve fibers, your care team may also consider other hereditary spastic paraplegia types or ataxia syndromes when symptoms change over time, and will coordinate treatment plans to reduce medication side effects and fall risk.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Throughout history, people have described stiff, tiring legs that worsened with distance, stairs, or time. In some families, several generations shared the same slow, spastic walk and frequent tripping, while others had milder changes that appeared later in life. Oral histories preserved patterns—grandparents who “walked on tiptoes,” parents who tired early, and children who began to notice tight calves in school sports.
From early theories to modern research, the story of autosomal dominant spastic paraplegia type 12 (SPG12) has moved from observation to explanation. Early medical reports grouped many types of inherited spastic paraplegia together because they looked similar on exam: stiff, scissoring gait; overactive reflexes; gradual progression. Doctors recognized that some forms ran strongly in families in a dominant pattern, but they could not tell one subtype from another without tools we have now. As medical science evolved, careful family trees and long-term follow-up showed that different subtypes could start at different ages, progress at different speeds, and sometimes include features beyond walking, such as mild weakness in the hands or changes in sensation.
In recent decades, knowledge has built on a long tradition of observation. Advances in genetics allowed researchers to separate what had been a wide, blended group into specific conditions, each linked to changes in a particular gene. SPG12 emerged within this framework as a dominantly inherited form tied to a single genetic change that disrupts nerve pathways controlling leg movement. Once considered rare, now recognized as part of a broader, better-defined group, SPG12 could be identified in families whose histories had puzzled clinicians for years.
Looking back helps explain why diagnoses were inconsistent. Without genetic testing, people with SPG12 were often labeled with general terms like “familial spastic paraplegia,” which made it hard to predict course or guide relatives about their own risks. Over time, descriptions became clearer: some families showed earlier onset in adolescence or young adulthood, while others noticed symptoms only in midlife. Not every early description was complete, yet together they built the foundation of today’s knowledge.
Today, the history of autosomal dominant spastic paraplegia type 12 underscores the value of combining lived experience, careful examination, and genetic tools. For many, this has meant moving from a vague label to a precise name, opening doors to tailored counseling, family planning discussions, and participation in research. The path from family stories to gene-based diagnosis continues to shape how SPG12 is understood and managed.